C
Celltrion Pharm Inc
KOSDAQ:068760
Celltrion Pharm Inc
KOSDAQ:068760
Price:
58 500
KRW
1.56%
Market Closed
Market Cap:
₩2.6T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
KR |
|
Goosehead Insurance Inc
NASDAQ:GSHD
|
US |
|
JMD Ventures Ltd
BSE:511092
|
IN |
|
Ssangyong Motor Co Ltd
KRX:003620
|
KR |
|
Guangdong Xiongsu Technology Group Co Ltd
SZSE:300599
|
CN |
|
S
|
Swarna Securities Ltd
BSE:531003
|
IN |
|
T
|
Tanfield Group PLC
LSE:TAN
|
UK |
|
Interpace Biosciences Inc
OTC:IDXG
|
US |
|
ITT Inc
NYSE:ITT
|
US |
|
People's Insurance Company Group of China Ltd
OTC:PINXF
|
CN |
|
Nagase Brothers Inc
TSE:9733
|
JP |
|
Indutrade AB
STO:INDT
|
SE |
|
M
|
Medifron DBT Co Ltd
KOSDAQ:065650
|
KR |
Multiples-Based Value
The Multiples-Based Value of one Celltrion Pharm Inc stock under the Base Case scenario is hidden KRW. Compared to the current market price of 58 500 KRW, Celltrion Pharm Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Celltrion Pharm Inc Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Celltrion Pharm Inc Competitors
Celltrion Pharm Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
2.6T KRW | 5 | 71.8 | 35.6 | 50 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
